InvestSMART

TrivarX Ltd (ASX:TRI)

ALERT: Price-sensitive ASX Announcement for TRI
Current share price for TRI : $0.016 -0.001 (-5.88%)+
Announcement
Release
18 Dec 2025 8:23AM
Price at Release
$0.017
Full Release
download
Summary
TrivarX Ltd announced positive results from a clinical trial involving US veterans, using their single-lead ECG algorithm to screen for major depressive episodes. Conducted in collaboration with the Greater Los Angeles Research and Education Foundation and the US Veterans Affairs Greater Los Angeles Healthcare System, the trial showed the algorithm's high sensitivity (97%) and specificity (64%) in detecting depression through heart rate metrics. The study also revealed a high prevalence of sleep disorders, depressive episodes, and PTSD in the veteran population. This innovative approach supports scalable mental health screening and aligns with VA initiatives, enhancing TrivarX's commercial and regulatory prospects for wider adoption.
Key Points
  • TrivarX Ltd achieved positive results from a US-veteran mental health trial using TRI’s single-lead technology.
  • The trial was conducted with the Greater Los Angeles Research and Education Foundation and the US Veterans Affairs Greater Los Angeles Healthcare System.
  • Results from 57 out of 60 patients showed high sensitivity and specificity for detecting major depressive episodes using TrivarX's single-lead ECG algorithm.
  • The algorithm demonstrated a sensitivity of 97% and specificity of 64% for detecting current major depressive episodes.
  • The study highlights the prevalence of sleep disturbance, major depressive episodes, and PTSD among veterans.
  • The single-lead ECG algorithm aligns with Veterans Affairs' priorities and strengthens TrivarX's commercial position.
  • The algorithm is scalable and can be integrated into existing clinical workflows, supporting early detection and personalized interventions.
  • The results bolster TrivarX's commercial positioning for broader clinical adoption.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.